Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Umbilical cord blood CD34+ progenitor-derived NK cells efficiently kill ovarian cancer spheroids and intraperitoneal tumors in NOD/SCID/IL2Rgnull mice.
Hoogstad-van Evert JS, Cany J, van den Brand D, Oudenampsen M, Brock R, Torensma R, Bekkers RL, Jansen JH, Massuger LF, Dolstra H. Hoogstad-van Evert JS, et al. Oncoimmunology. 2017 May 11;6(8):e1320630. doi: 10.1080/2162402X.2017.1320630. eCollection 2017. Oncoimmunology. 2017. PMID: 28919991 Free PMC article.
TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer.
Maas RJ, Hoogstad-van Evert JS, Van der Meer JM, Mekers V, Rezaeifard S, Korman AJ, de Jonge PK, Cany J, Woestenenk R, Schaap NP, Massuger LF, Jansen JH, Hobo W, Dolstra H. Maas RJ, et al. Among authors: hoogstad van evert js. Oncoimmunology. 2020 Nov 8;9(1):1843247. doi: 10.1080/2162402X.2020.1843247. Oncoimmunology. 2020. PMID: 33224630 Free PMC article.
CD34+ progenitor-derived NK cell and gemcitabine combination therapy increases killing of ovarian cancer cells in NOD/SCID/IL2Rgnull mice.
Van der Meer JMR, de Jonge PKJD, van der Waart AB, Geerlings AC, Moonen JP, Brummelman J, de Klein J, Vermeulen MC, Maas RJA, Schaap NPM, Hoogstad-van Evert JS, Ottevanger PB, Jansen JH, Hobo W, Dolstra H. Van der Meer JMR, et al. Among authors: hoogstad van evert js. Oncoimmunology. 2021 Oct 1;10(1):1981049. doi: 10.1080/2162402X.2021.1981049. eCollection 2021. Oncoimmunology. 2021. PMID: 34616589 Free PMC article.
Harnessing natural killer cells for the treatment of ovarian cancer.
Hoogstad-van Evert JS, Bekkers R, Ottevanger N, Jansen JH, Massuger L, Dolstra H. Hoogstad-van Evert JS, et al. Gynecol Oncol. 2020 Jun;157(3):810-816. doi: 10.1016/j.ygyno.2020.03.020. Epub 2020 Apr 5. Gynecol Oncol. 2020. PMID: 32268953 Free article. Review.
Correction to: IL‑15 superagonist N‑803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor‑derived NK cells.
Van der Meer JMR, Maas RJA, Guldevall K, Klarenaar K, De Jonge PKJD, Hoogstad-van Evert JS, van der Waart AB, Cany J, Safrit JT, Lee JH, Wagena E, Friedl P, Önfelt B, Massuger LF, Schaap NPM, Jansen JH, Hobo W, Dolstra H. Van der Meer JMR, et al. Among authors: hoogstad van evert js. Cancer Immunol Immunother. 2021 Nov;70(11):3367. doi: 10.1007/s00262-021-03049-5. Cancer Immunol Immunother. 2021. PMID: 34524494 Free PMC article. No abstract available.
The effect of subcellular localization on the efficiency of EGFR-targeted VHH photosensitizer conjugates.
van Lith SAM, van den Brand D, Wallbrecher R, Wübbeke L, van Duijnhoven SMJ, Mäkinen PI, Hoogstad-van Evert JS, Massuger L, Ylä-Herttuala S, Brock R, Leenders WPJ. van Lith SAM, et al. Among authors: hoogstad van evert js. Eur J Pharm Biopharm. 2018 Mar;124:63-72. doi: 10.1016/j.ejpb.2017.12.009. Epub 2017 Dec 20. Eur J Pharm Biopharm. 2018. PMID: 29274374 Free article.
The Promises of Natural Killer Cell Therapy in Endometriosis.
Hoogstad-van Evert J, Paap R, Nap A, van der Molen R. Hoogstad-van Evert J, et al. Int J Mol Sci. 2022 May 16;23(10):5539. doi: 10.3390/ijms23105539. Int J Mol Sci. 2022. PMID: 35628346 Free PMC article. Review.
15 results